Lartruvo fails confirmatory study; Lilly suspending promotion

Eli Lilly and Co. (NYSE:LLY) said on Jan. 18 that it will suspend promotion of Lartruvo olaratumab after it missed the primary endpoints of the Phase III ANNOUNCE trial to treat advanced or metastatic soft tissue sarcoma. The trial was designed as a

Read the full 437 word article

User Sign In